 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 24 concerning MorphoSys AG
|
-
DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody Therapies
(03/27/2008)
MorphoSys AG announced that DAIICHI SANKYO COMPANY, LIMITED has triggered its pre-existing option to extend the current collaboration between the two companies. The collaboration, originally signed in March 2006, was to end in March 2008. Under the ...
-
Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
(02/28/2008)
AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich
Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify ...
-
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
(02/26/2008)
MorphoSys AG announced that Astellas Pharma Inc. has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term. Under the agreement, which is now extended ...
-
MorphoSys Discloses GM-CSF as Target of MOR103 Program
(01/18/2008)
Exclusive License Obtained to Key Patent from the University of Melbourne
MorphoSys AG disclosed that human cytokine GM-CSF (Granulocyte macrophage-colony stimulating factor) is the target molecule for the company's proprietary MOR103 antibody program for the treatment of rheumatoid arthritis (RA). MOR103 is the first ...
-
MorphoSys and Novartis Forge New Strategic Alliance to Establish Innovative Therapeutic Antibody Pipeline
(12/04/2007)
MorphoSys to become Novartis's main technology collaborator in the area of antibody discovery and development
MorphoSys AG announced the formation of one of the most comprehensive strategic alliances with Novartis in the discovery and development of biopharmaceuticals. The deal is aimed at establishing a pipeline of innovative drugs, and combines ...
-
MorphoSys Granted Further U.S. Patent for its Core Antibody Technology HuCAL
(09/27/2007)
MorphoSys AG announced that the U.S. Patent & Trademark Office has granted a fifth U.S. patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection to MorphoSys's core technology. ...
-
MorphoSys Announces Change in Supervisory Board
(03/27/2007)
Supervisory Board Nominates Walter Blättler as Successor of Andreas Plückthun
MorphoSys AG announced that its current board member Professor Andreas Plückthun intends to resign from the Supervisory Board with effect of 16 May, 2007. Professor Plückthun is leaving the board at his own request, in order to devote additional ...
-
MorphoSys's AbD Serotec Expands Antibody License Agreement with Medical Research Council
(03/21/2007)
MorphoSys AG announced that its business unit AbD Serotec has significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of Great Britain's Medical Research Council (MRC). The agreement, which provides AbD ...
-
IBA Announces Expansion of Collaboration with MorphoSys's AbD Serotec
(12/06/2006)
IBA GmbH announced the signing of a second license agreement with MorphoSys AG regarding recombinant antibody purification using IBA's proprietary Strep-tag® technology. The original research license agreement dating back to the year 2000 has now ...
-
MorphoSys Announces Expansion of Collaboration with Novartis
(06/27/2006)
MorphoSys AG announced an expansion of its existing therapeutic antibody collaboration with Novartis. The original collaboration agreement provided for a three-year term with an option for Novartis to extend. The collaboration will now go through ...
Additional information
MorphoSys AG
Martinsried/Planegg, Germany
Company
|
|
|
|
Top
